v3.25.1
Revenue Recognition - Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Loss (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Profit (Loss) [Line Items]        
Revenue $ 1,364,341 $ 817,034 $ 4,107,494 $ 2,409,953
Cost of revenue 420,447 248,043 1,284,375 734,285
Gross profit $ 943,894 568,991 $ 2,823,119 1,675,668
Gross Profit % 69.18%   68.73%  
Assets $ 3,980,768   $ 3,821,429 [1] 2,879,103
Net profit (loss) (760,040) $ (1,961,020) (5,562,971) $ (9,813,666)
Global Stem Cells Group [Member]        
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Profit (Loss) [Line Items]        
Revenue 1,364,341   4,107,494  
Cost of revenue 420,447   1,284,375  
Gross profit $ 943,894   $ 2,823,119  
Gross Profit % 69.18%   68.73%  
Assets $ 2,138,933   $ 1,951,853  
Net profit (loss) 91,887   $ 303,730  
Regenerative Medical Technology Group [Member]        
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Profit (Loss) [Line Items]        
Revenue      
Cost of revenue      
Gross profit      
Gross Profit % 0.00%      
Assets $ 1,841,835      
Net profit (loss) $ (851,927)      
[1] Derived from audited information